{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:15Z","timestamp":1760144715499,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The aim of this study was to evaluate outcomes of transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) in patients previously treated with transarterial embolization (TAE). In this retrospective study, all HCC patients who received TARE from 1\/2012 to 12\/2022 for treatment of residual or recurrent disease after TAE were identified. Overall survival (OS) was estimated using the Kaplan\u2013Meier method. Univariate Cox regression was performed to determine significant predictors of OS after TARE. Twenty-one patients (median age 73.4 years, 18 male, 3 female) were included. Median dose to the perfused liver volume was 121 Gy (112\u2013444, range), and 18\/21 (85.7%) patients received 112\u2013140 Gy. Median OS from time of HCC diagnosis was 32.9 months (19.4\u201361.4, 95% CI). Median OS after first TAE was 29.3 months (15.3\u201358.9, 95% CI). Median OS after first TARE was 10.6 months (6.8\u201327.0, 95% CI). ECOG performance status of 0 (p = 0.038), index tumor diameter &lt; 4 cm (p = 0.022), and hepatic tumor burden &lt; 25% (p = 0.018) were significant predictors of longer OS after TARE. TARE may provide a survival benefit for appropriately selected patients with HCC who have been previously treated with TAE.<\/jats:p>","DOI":"10.3390\/curroncol31050200","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T03:23:19Z","timestamp":1715138599000},"page":"2650-2661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization"],"prefix":"10.3390","volume":"31","author":[{"given":"Ken","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Karimi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Marinelli","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-727X","authenticated-orcid":false,"given":"Joseph P.","family":"Erinjeri","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7278-1369","authenticated-orcid":false,"given":"Vlasios S.","family":"Sotirchos","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-4310","authenticated-orcid":false,"given":"James J.","family":"Harding","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-017X","authenticated-orcid":false,"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Covey","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-1399","authenticated-orcid":false,"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 56, 908\u2013943.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared with Embolization with Microspheres Alone","volume":"34","author":"Brown","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Roth, G.S., Benhamou, M., Teyssier, Y., Seigneurin, A., Abousalihac, M., Sengel, C., Seror, O., Ghelfi, J., Ganne-Carrie, N., and Blaise, L. (2021). Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers, 13.","DOI":"10.3390\/cancers13040812"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jvir.2009.12.390","article-title":"Arterial patency after repeated hepatic artery bland particle embolization","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.acra.2017.12.011","article-title":"Evaluation of the Effect of Operator Experience on Outcome of Hepatic Artery Embolization of Hepatocellular Carcinoma in a Tertiary Cancer Center","volume":"25","author":"Yarmohammadi","year":"2018","journal-title":"Acad. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1245\/s10434-022-12036-8","article-title":"Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses","volume":"29","author":"Ilagan","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00270-023-03388-z","article-title":"Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series","volume":"46","author":"Srinivas","year":"2023","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000368142","article-title":"Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.jvir.2023.08.039","article-title":"Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry","volume":"34","author":"Hund","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00270-017-1739-5","article-title":"Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation","volume":"40","author":"Klompenhouwer","year":"2017","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1346550","DOI":"10.3389\/fradi.2024.1346550","article-title":"Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization","volume":"4","author":"Wagenpfeil","year":"2024","journal-title":"Front. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.27304","article-title":"LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions","volume":"61","author":"Mitchell","year":"2015","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.hpb.2019.08.004","article-title":"Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: Analysis of outcome and liver function at disease progression","volume":"22","author":"Borgheresi","year":"2020","journal-title":"HPB"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","article-title":"Radioembolization with 90Y microspheres: Angiographic and technical considerations","volume":"30","author":"Lewandowski","year":"2007","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/01.RVI.0000236744.34720.73","article-title":"Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 3: Comprehensive literature review and future direction","volume":"17","author":"Salem","year":"2006","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","article-title":"Clinical and dosimetric considerations for Y90: Recommendations from an international multidisciplinary working group","volume":"46","author":"Salem","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","unstructured":"(2023, November 02). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_22","unstructured":"(2021). R-Core-Team R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2967\/jnumed.117.202937","article-title":"Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome","volume":"59","author":"Kafrouni","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00270-022-03139-6","article-title":"Optimizing (90)Y Particle Density Improves Outcomes After Radioembolization","volume":"45","author":"Maxwell","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:25Z","timestamp":1760107285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["curroncol31050200"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31050200","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}